Memantine augmentation of cognitive training in schizophrenia
Memantine augmentation of cognitive training in schizophrenia
批准号:
10596484
负责人:
GREGORY A LIGHT
金额:
$74.13万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-02-16 至 2024-12-31
关键词:
AddressAffectAlzheimer&aposs DiseaseAntipsychotic AgentsAuditoryBiological AssayBiological MarkersChronicClinicClinicalClinical TrialsCognitionCognitiveCognitive TherapyDoseDouble-Blind MethodEducational InterventionEffectivenessElectroencephalographyElectrophysiology (science)ExerciseExhibitsExposure toFDA approvedFamilyFutureHealth systemHourImpaired cognitionImpairmentInterventionLaboratoriesLearningLifeMeasuresMedicineMemantineMemoryMeta-AnalysisN-Methyl-D-Aspartate ReceptorsNeurocognitiveNeuronal PlasticityOutcomeOutcome MeasureParticipantPatient-Focused OutcomesPatientsPerceptual learningPerformancePharmaceutical PreparationsPlacebo ControlPlacebosProcessPsychotic DisordersRandomizedRecoveryResourcesSafetySchizophreniaSensorySymptomsTestingTherapeuticTimeTraining ProgramsVerbal Learningarmauditory discriminationbiomarker identificationcognitive benefitscognitive functioncognitive trainingcomputerizedconfirmatory trialcostdesigndisabilityearly detection biomarkerseffective therapyfunctional gainhigh rewardhigh riskimprovedinformation processingneurophysiologyneuropsychiatrynovelnovel strategiespatient subsetsperformance based measurementpharmacologicpillpilot testpilot trialpredictive markerpsychosocialpsychotic symptomsrandomized, controlled studyresponsescreeningsoundtherapy designtreatment armtreatment responsetreatment strategy
中文摘要
作为对RFA-MH-18-705的回应,本申请开发并测试了一种新的治疗策略,
精神分裂症(SZ)患者的认知,通过认知疗法的药物增强
(PACTs),并直接解决了对这些致残性损伤的更有效治疗的迫切需求。
SZ患者的认知益处可以通过“自下而上”的基于感觉的定向认知训练来实现
(TCT)治疗,但这种治疗是时间和资源密集型的,反应是不完整的,
变量这个应用程序测试了一个合理的和经验支持的平台,以增加TCT的好处
在抗精神病药物治疗的SZ患者中,通过每日连续治疗20 mg美金刚胺(MEM),FDA
批准用于治疗阿尔茨海默病认知功能障碍的药物。近期荟萃分析
在接受抗精神病药物治疗的SZ患者中,MEM强化治疗的安全性、耐受性和
在提高简短的认知筛查测试分数方面的有效性。我们假设MEM会增加
TCT学习,因此从TCT中获得临床收益,这种PACT方法将是最有效的
在生物标志物定义的患者亚组中。对这些假设的初步支持来自我们的
MEM相对于安慰剂单次给药暴露的概念验证、随机化、对照研究。在这些
研究中,我们发现MEM显著增强了听觉辨别力的学习,听觉辨别力的关键组成部分,
TCT程序,已知该程序可在30- 50小时TCT后驱动SZ患者的认知增益。我们也
发现单剂量MEM显著增强了早期感觉信息的几种生物标志物
抗精神病药物治疗SZ患者的处理。剂量反应和时间过程研究确定了
最佳MEM剂量(20 mg),以获得最大的促学习效果。本申请对以下方面进行了仔细评估:
SZ的PACT策略:目标1)确认目标接合:将对54名SZ患者进行测试,
证实MEM(20 mg)增强TCT学习的测量;目标2)有效的试点测试:来自
目标1将随机分配至2个治疗组(n=27/组),进行30次双盲安慰剂对照治疗
MEM+TCT与安慰剂+TCT的临床试验,以确定每日给予MEM是否增加了
TCT增益的幅度、速率和/或持久性,以及这些增益是否与目标
参与,使用特定的Go/No-Go标准和症状,认知和现实生活的结局指标
3)基于认知,
TCT前后评估的电生理和基于性能的测量。这是一个非常新颖的,
高风险高回报的应用,以开发一种基于PACT的治疗模式,
改善精神分裂症患者的康复和改善预后,并将决定未来,
这种方法的完全有效的“抗炎疗效试验”是必要的。
英文摘要
In response to RFA-MH-18-705, this application develops and tests a novel treatment strategy for improving
cognition in patients with schizophrenia (SZ), via Pharmacologic Augmentation of Cognitive Therapies
(PACTs), and directly addresses a critical need for more effective treatments for these disabling impairments.
Cognitive benefits in SZ patients can be achieved via “bottom-up” sensory-based targeted cognitive training
(TCT) therapies, but such treatments are time- and resource-intensive, and responses are incomplete and
variable. This application tests a rational and empirically supported platform for augmenting the benefits of TCT
in antipsychotic medicated SZ patients by adjunctive daily treatment of 20 mg memantine (MEM), an FDA
approved medication for the treatment of cognitive dysfunction in Alzheimer's Disease. Recent meta-analyses
of MEM augmentation in antipsychotic-medicated SZ patients have demonstrated its safety, tolerability, and
effectiveness at improving scores on brief cognitive screening tests. We hypothesize that MEM will augment
TCT learning and hence the clinical gains from TCT, and that this PACT approach will be most effective
in biomarker-defined subgroups of patients. Preliminary support for these hypotheses comes from our
proof-of-concept, randomized, controlled studies of single-dose exposure to MEM relative to placebo. In these
studies, we found that MEM significantly enhanced learning in auditory discrimination, the key component of
the TCT program which is known to drive the cognitive gains in SZ patients following 30-50h of TCT. We also
found that a single dose of MEM significantly enhanced several biomarkers of early sensory information
processing in antipsychotic medicated SZ patients. Dose-response and time course studies identified the
optimal MEM dose (20 mg) for maximal pro-learning effects. This application conducts a careful assessment of
this PACT strategy for SZ: Aim 1) Confirmation of target engagement: 54 SZ patients will be tested to
confirm that MEM (20 mg) enhances measures of TCT learning; Aim 2) Efficient pilot testing: Subjects from
Aim 1 will be randomized into 2 treatment arms (n=27/arm) for a double-blind placebo-controlled 30-session
clinical trial of MEM+TCT vs. placebo+TCT, to determine whether daily dosing of MEM augments the
magnitude, rate and/or durability of TCT gains, and whether these gains are associated with target
engagement, using specific Go/No-Go criteria and outcome measures of symptoms, cognition and real-life
function; Aim 3) Predictive biomarker identification of the PACT response, based on cognitive,
electrophysiological, and performance-based measures assessed pre- and post-TCT. This is a highly novel,
high-risk high-reward application to develop a PACT-based treatment paradigm that will enhance cognition,
improve recovery and enhance outcomes for patients with schizophrenia, and will determine whether a future,
fully-powered “Confirmatory Efficacy trial” of this approach is warranted.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Memantine augmentation of cognitive training in schizophrenia
-
批准号:10353409
-
项目类别:
-
资助金额:$75.28万
-
财政年份:2021
-
负责人:GREGORY A LIGHT
-
依托单位:
Pathway(s) From Genes to Functional Deficits of Schizophrenia Patients
-
批准号:7644345
-
项目类别:
-
资助金额:$34.76万
-
财政年份:2007
-
负责人:GREGORY A LIGHT
-
依托单位:
Pathway(s) From Genes to Functional Deficits of Schizophrenia Patients
-
批准号:7845512
-
项目类别:
-
资助金额:$34.76万
-
财政年份:2007
-
负责人:GREGORY A LIGHT
-
依托单位:
Pathway(s) From Genes to Functional Deficits of Schizophrenia Patients
-
批准号:7233011
-
项目类别:
-
资助金额:$34.76万
-
财政年份:2007
-
负责人:GREGORY A LIGHT
-
依托单位:
海外基金